These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 24095875)

  • 1. Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study.
    Jara GE; Vera DM; Pierini AB
    J Mol Graph Model; 2013 Nov; 46():10-21. PubMed ID: 24095875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein.
    Pajeva IK; Sterz K; Christlieb M; Steggemann K; Marighetti F; Wiese M
    ChemMedChem; 2013 Oct; 8(10):1701-13. PubMed ID: 23943604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators.
    Globisch C; Pajeva IK; Wiese M
    Bioorg Med Chem; 2006 Mar; 14(5):1588-98. PubMed ID: 16307883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of Multidrug Resistance in Mouse Lymphoma Cells by Extracts and Flavonoids from Pistacia integerrima.
    Rauf A; Uddin G; Raza M; Ahmad B; Jehan N; Siddiqui BS; Molnar J; Csonka A; Szabo D
    Asian Pac J Cancer Prev; 2016; 17(1):51-5. PubMed ID: 26838254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses.
    Kadioglu O; Saeed ME; Valoti M; Frosini M; Sgaragli G; Efferth T
    Biochem Pharmacol; 2016 Mar; 104():42-51. PubMed ID: 26807479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein.
    Loo TW; Clarke DM
    J Biol Chem; 2015 Dec; 290(49):29389-401. PubMed ID: 26507655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein.
    Ferreira RJ; Ferreira MJ; dos Santos DJ
    J Chem Inf Model; 2013 Jul; 53(7):1747-60. PubMed ID: 23802684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QSAR studies of macrocyclic diterpenes with P-glycoprotein inhibitory activity.
    Sousa IJ; Ferreira MJ; Molnár J; Fernandes MX
    Eur J Pharm Sci; 2013 Feb; 48(3):542-53. PubMed ID: 23228414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homology modeling and binding site assessment of the human P-glycoprotein.
    Tarcsay A; Keseru GM
    Future Med Chem; 2011 Mar; 3(3):297-307. PubMed ID: 21446844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.
    Boumendjel A; Di Pietro A; Dumontet C; Barron D
    Med Res Rev; 2002 Sep; 22(5):512-29. PubMed ID: 12210557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance.
    Bois F; Beney C; Boumendjel A; Mariotte AM; Conseil G; Di Pietro A
    J Med Chem; 1998 Oct; 41(21):4161-4. PubMed ID: 9767651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells.
    Gopinath VS; Thimmaiah P; Thimmaiah KN
    Bioorg Med Chem; 2008 Jan; 16(1):474-87. PubMed ID: 17933543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Drug Transport Pathways through Human P-Glycoprotein.
    McCormick JW; Vogel PD; Wise JG
    Biochemistry; 2015 Jul; 54(28):4374-90. PubMed ID: 26125482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico study of desmosdumotin as an anticancer agent: homology modeling, docking and molecular dynamics simulation approach.
    Gadhe CG; Kothandan G; Cho SJ
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1636-44. PubMed ID: 23796247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations.
    Liu M; Hou T; Feng Z; Li Y
    J Biomol Struct Dyn; 2013; 31(6):612-29. PubMed ID: 22888853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds.
    Ngo TD; Tran TD; Le MT; Thai KM
    Mol Divers; 2016 Nov; 20(4):945-961. PubMed ID: 27431577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators.
    Klinkhammer W; Müller H; Globisch C; Pajeva IK; Wiese M
    Bioorg Med Chem; 2009 Mar; 17(6):2524-35. PubMed ID: 19250834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.